Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 18, 2021 - Issue 12
Submit an article Journal homepage
2,521
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Targeting genetic tool for long non-coding RNA of cancer stem cells with aptamer-guided nanocarriers

Yazid Zaikia Non-Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi Mara Selangor, Puncak Alam, Malaysia;b Particle Design Research Group, Faculty of Pharmacy, Universiti Teknologi Mara Selangor, Puncak Alam, MalaysiaView further author information
&
Tin Wui Wonga Non-Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi Mara Selangor, Puncak Alam, Malaysia;b Particle Design Research Group, Faculty of Pharmacy, Universiti Teknologi Mara Selangor, Puncak Alam, Malaysia;c Sino-Malaysia Molecular Oncology and Traditional Chinese Medicine Delivery Joint Research Centre, Medical College, Yangzhou University, ChinaCorrespondence[email protected]
View further author information
Pages 1791-1793 | Received 07 Aug 2021, Accepted 01 Oct 2021, Published online: 14 Oct 2021

References

  • Huang X, Xiao R, Pan S, et al. Uncovering the roles of long non-coding RNAs in cancer stem cells. J Hematol Oncol. 10(1): 62. 2017.
  • Shibata M, Hoque MO. Targeting cancer stem cells: a strategy for effective eradication of cancer. Cancers (Basel). 2019;11(5):732.
  • Zhou G, Latchoumanin O, Bagdesar M, et al. Aptamer-based therapeutic approaches to target cancer stem cells. Theranostics. 2017;7(16):3948–3961.
  • Heery R, Finn S, Cuffe S, et al. Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers (Basel). 2017;9(12):38.
  • Nair N, Calle AS, Zahra M, et al. A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment. Sci Rep. 7(1): 6838. 2017.
  • Desai A, Yan Y, Gerson SL. Concise reviews: cancer stem cell targeted therapies: toward clinical success. Stem Cells Transl Med. 2017;8(1):75–81.
  • Vidovic D, Huynh TT, Konda P, et al. ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells. Cell Death Differ. 2020;27(1):363–378.
  • Zhu Q, Wang G, Guo Y, et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget. 2017;8:91990–92003.
  • Subhan MA, Torchilin VP. Efficient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res. 2019;214:62–91.
  • Zhen S, Takahashi Y, Narita S, et al. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. Oncotarget. 2017;8(6):9375–9387.
  • Zhen S, Li X. Application of CRISPR-Cas9 for long noncoding RNA genes in cancer research. Hum Gene Ther. 2019;30(1):3–9.
  • Musalli AH, Talukdar PD, Roy P, et al. Folate-induced nanostructural changes of oligochitosan nanoparticles and their fate of cellular internalization by melanoma. Carbohydr Polym. 2020;244:116488.
  • Rasul RM, Muniandy MT, Zakaria Z, et al. A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers. Carbohydr Polym. 2020;250:116800.
  • Musa N, Wong TW. Design of polysaccharidic nano-in-micro soft agglomerates as primary oral drug delivery vehicle for colon-specific targeting. Carbohydr Polym. 2020;247:116673.
  • Moitra P, Misra SK, Kumar K, et al. Cancer stem cell-targeted gene delivery mediated by aptamer-decorated pH-sensitive nanoliposomes. ACS Biomater Sci Eng. 7(6): 2508–2519. 2021.
  • Singh VK, Saini A, Chandra R. The implications and future perspectives of nanomedicine for cancer stem cell targeted therapies. Front Mol Biosci. 2017;4(52):1–21.
  • Zhou G, Da Won Bae S, Nguyen R, et al. An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells. Cancer Lett. 2021;501:124–132.
  • Xiang D, Shigdar S, Bean AG, et al. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics. 7(17): 4071–4086. 2017.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.